 Adaptimmune Therapeutics plc NASDAQ: ADAP has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG OTC: RHHBY, to develop and commercialize allogeneic cell therapies for oncology indications. The collaboration includes developing allogeneic T-cell therapies for up to five shared cancer targets and personalized allogeneic T-cell therapies. 